Clinical Trial Update: Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab for metastatic or unresectable small intestinal adenocarcinoma, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Intestinal Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-01-10